Patient demographics, selected laboratory values, clinical history, and immunotherapy drugs included in this study
Age | |
Median | 53.5 |
Range | 18–84 |
Sex | |
Female | 29 |
Male | 21 |
No. of metastatic sites | |
< 3 | 37 |
> =3 | 13 |
LDH | |
< =ULN | 36 |
> ULN | 14 |
ECOG PS | |
0–1 | 48 |
2 | 2 |
Albumin | |
> =3.5 g/dl | 46 |
< 3.5 g/dl | 4 |
RMH score | |
< 2 | 43 |
> =2 | 7 |
Prior treatments | |
Median | 3 |
Range | 0–12 |
Anthracycline | 30 |
Ifosfamide | 14 |
Gemcitabine | 22 |
Docetaxel | 13 |
Platinum | 8 |
Investigational therapies | |
anti-CCR4 and anti-PD-L1 | 4 |
anti-PD-1 | 7 |
anti-PD-L1 | 7 |
anti-TIM-3 | 1 |
anti-CTLA-4 | 5 |
anti-CTLA-4 and immunomodulator | 7 |
anti-CTLA-4 and KIT inhibitor | 10 |
Dendritic cell vaccine | 7 |
Interleukin-2 | 1 |
anti-TGF-β | 1 |